Exonic duplications account for 10%–15% of all mutations in Duchenne muscular dystrophy (DMD), a severe hereditary neuromuscular disorder. We report a CRISPR (clustered regularly interspaced short palindromic repeat)/Cas9-based strategy to correct the most frequent (exon 2) duplication in the DMD gene by targeted deletion, and tested the efficacy of such an approach in patient-derived myogenic cells. We demonstrate restoration of wild-type dystrophin expression at transcriptional and protein level in myotubes derived from genome-edited myoblasts in the absence of selection. Removal of the duplicated exon was achieved by the use of only one guide RNA (gRNA) directed against an intronic duplicated region, thereby increasing editing efficiency and reducing the risk of off-target effects. This study opens a novel therapeutic perspective for patients carrying disease-causing duplications.

Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System / Lattanzi, A.; Moiani, A.; Izmiryan, A.; Martin, S.; Mavilio, F.; Bovolenta, M.; Duguez, S.; Mamchaoui, K.; Mouly, V.; Barbon, E.; Bernardi, F.. - In: MOLECULAR THERAPY NUCLEIC ACIDS. - ISSN 2162-2531. - 7:(2017), pp. 11-19. [10.1016/j.omtn.2017.02.004]

Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System

Mavilio F.;
2017

Abstract

Exonic duplications account for 10%–15% of all mutations in Duchenne muscular dystrophy (DMD), a severe hereditary neuromuscular disorder. We report a CRISPR (clustered regularly interspaced short palindromic repeat)/Cas9-based strategy to correct the most frequent (exon 2) duplication in the DMD gene by targeted deletion, and tested the efficacy of such an approach in patient-derived myogenic cells. We demonstrate restoration of wild-type dystrophin expression at transcriptional and protein level in myotubes derived from genome-edited myoblasts in the absence of selection. Removal of the duplicated exon was achieved by the use of only one guide RNA (gRNA) directed against an intronic duplicated region, thereby increasing editing efficiency and reducing the risk of off-target effects. This study opens a novel therapeutic perspective for patients carrying disease-causing duplications.
2017
10-feb-2017
7
11
19
Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System / Lattanzi, A.; Moiani, A.; Izmiryan, A.; Martin, S.; Mavilio, F.; Bovolenta, M.; Duguez, S.; Mamchaoui, K.; Mouly, V.; Barbon, E.; Bernardi, F.. - In: MOLECULAR THERAPY NUCLEIC ACIDS. - ISSN 2162-2531. - 7:(2017), pp. 11-19. [10.1016/j.omtn.2017.02.004]
Lattanzi, A.; Moiani, A.; Izmiryan, A.; Martin, S.; Mavilio, F.; Bovolenta, M.; Duguez, S.; Mamchaoui, K.; Mouly, V.; Barbon, E.; Bernardi, F....espandi
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S2162253117301300-main.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 1.21 MB
Formato Adobe PDF
1.21 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1199453
Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 40
social impact